Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Central Nervous System Lymphoma: early-phase trial registry
7 of 15 indexed Central Nervous System Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 7 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Central Nervous System Lymphoma: 15 US clinical trials tracked, 7 recruiting.
Central Nervous System Lymphoma is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition central-nervous-system-lymphoma
OPEN 7 | RECR 47% | LATE 0 | EARLY 11 | RANK #1140 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Autism (47% recruiting · 105 trials)
Central Nervous System Lymphoma lists 7 open slots (47% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Central Nervous System Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Central Nervous System Lymphoma recruits in line with its size-band peers.
7 of 15 indexed trials (46.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Central Nervous System Lymphoma research.
Memorial Sloan Kettering Cancer Center accounts for 3 of 15 trials (20%). 12 distinct sponsors appear on at least one study for this condition label.
-
Most Central Nervous System Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 49 among the 15 trials that report a genuine target (sentinel values excluded). 9 of those (60%) plan for fewer than 100 participants.
-
Central Nervous System Lymphoma research is mostly interventional.
12 interventional and 3 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Medical College of Wisconsin
NCT03375619
DALY II USA/ MB-CART2019.1 for DLBCL
Miltenyi Biomedicine
NCT04792489
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Medical College of Wisconsin
NCT04186520
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
M.D. Anderson Cancer Center
NCT05011045
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
Memorial Sloan Kettering Cancer Center
NCT07082868
Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma
City of Hope Medical Center
NCT05625594
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)
University of Utah
NCT06607549
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Cellectar Biosciences
NCT02952508
LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma
Memorial Sloan Kettering Cancer Center
NCT03684980
Acalabrutinib in CNSL
Dana-Farber Cancer Institute
NCT04906902
Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
National Cancer Institute (NCI)
NCT03964090
A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
UNC Lineberger Comprehensive Cancer Center
NCT04548648
Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
OHSU Knight Cancer Institute
NCT00103038
Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)
Massachusetts General Hospital
NCT00916630
Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity
Memorial Sloan Kettering Cancer Center
NCT03342586
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Central Nervous System Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Central Nervous System Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Central Nervous System Lymphoma page
15 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Central Nervous System Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Central Nervous System Lymphoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Central Nervous System Lymphoma condition card totals 15 registered trials; most-linked intervention Acalabrutinib; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.